tbuckley/cabot-search huggingface dataset:
Abstract 15218: Neutrophil to Lymphocyte ratio Predicts All-cause Mortality in Patients with Chronic Heart Failure
Authors: Mohapradeep Mohan, Harshal Deshmukh, Fatima Baig, Sean Hawkey, Lynn Rutherford, Allan Struthers, Anna Maria, Chim Lang
Journal: Circulation (2014)

Introduction: Chronic heart failure (CHF) patients are characterised by systemic inflammation and there is increasing evidence that this may contribute to the development and progression of heart failure. Neutrophil to Lymphocyte ratio (NLR), a composite inflammatory marker, has been shown as a predictor of adverse outcomes in critically ill patients. Hypothesis: In this study, we assessed the hypothesis that NLR is associated with poor prognosis in CHF patients. Methods: Patients with medical conditions known to affect the total and differential WBC counts were excluded from the analyses. After exclusion, a total of 1679 patients with CHF (mean age 75±10, 45% females, 95% IHD; 56% in NYHA III/IV) were evaluated prospectively from the BIOSTAT-CHF Scotland cohort. NLR was used as a categorical variable (above and below the median). A Cox proportional Hazard model was used to investigate the effect of NLR on all-cause mortality, adjusting for age, sex, BMI, eGFR, SBP, LDL and haemoglobin. Results: During a ...
Non-steroidal anti-inflammatory drugs reactivate SPARC expression via promoter demethylation in human lung cancer cells to inhibit cell invasion
Authors: Wen-Chun Hung
Journal: Clinical Cancer Research (2007)

B11   Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to exhibit potential anti-metastatic and anti-angiogeneic effect  in vivo  and  in vitro . One of the mechanisms by which NSAIDs suppress tumorigenesis is inhibition of angiogenesis and metastasis. In this study, we used microarray system to study the change of expression profile of metastasis-related genes regulated by NS398, a NSAID and cyclooxygenase-2 (COX-2) inhibitor. We found that several negative regulators of cell invasion including secreted protein acidic and rich in cycteine (SPARC), thrombospondin 1 (TSP1), thrombospondin 3 (TSP3) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) are up-regulated by NS398. Functional assay indicated that SPARC is a critical mediator for NSAIDs to inhibit cell invasion. More importantly, we demonstrated that up-regulation of SPARC expression in human lung cancer cells is mediated via inhibition of DNA methyltransferase (DNMT) expression and promoter demethylation. This is the first report to show that NSAIDs may inhibit the expression of DNMT 1 and 3b to reverse promoter methylation and to reactivate the expression of tumor suppressor genes such as SPARC in cancer cells to inhibit cell invasion. Our results provide new insights for the understanding of the anti-cancer actions of NSAIDs.
Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States
Authors: Philip S Rosenberg, Kimberly A Barker, William F Anderson
Journal: JNCI Journal of the National Cancer Institute (2015)

No study has predicted the future incidence rate and annual burden (number) of new cases in the United States of invasive and in situ female breast cancers stratified by the estrogen receptor (ER) status. We constructed forecasts for women age 30 to 84 years in 2011 through 2030 using cancer incidence data from the Surveillance, Epidemiology, and End Results Program, novel age-period-cohort forecasting models, and population projections from the US Census Bureau. The total number of new tumors (invasive plus in situ) is expected to rise from 283 000 in 2011 to 441 000 in 2030 (plausible range 353 500 to 466 700 cases). The proportion of all new case patients age 70 to 84 years is expected to increase from 24.3% to 34.8%, while the proportion ages 50 to 69 years is expected to decrease from 54.7% to 43.6%. The proportion of ER-positive invasive cancers is expected to remain nearly the same at 62.6%, whereas the proportion of ER-positive in situ cancers is expected to increase from 19.1% to 28.9%. The proportion of ER-negative cancers (invasive and in situ) is expected to decrease from 16.8% to 8.6%. Breast cancer overall will rise in the United States through 2030, especially for ER-positive in situ tumors among women age 70 to 84 years. In contrast, ER-negative invasive and in situ tumors will fall, for reasons that are not fully understood. These results highlight a need to optimize case management among older women, characterize the natural history of in situ cancers, and identify those factors responsible for declining ER-negative incidence.
Clarification on Buprenorphine
Authors: Jane E. Henney
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1898: The combination of gemcitabine/nab-paclitaxel and anti-DLL4 (demcizumab) produces synergistic growth inhibition, delays tumor recurrence and reduces tumor initiating cells in pancreatic cancer
Authors: Wan-Ching Yen, Marcus Fischer, John Lewicki, Austin Gurney, Timothy Hoey
Journal: Cancer Research (2014)

Abstract Clinical management of pancreatic cancer is challenging and this disease remains the fourth most common cause of cancer-related death. Conventional chemotherapeutic agents, including gemcitabine, commonly used in the treatment of pancreatic cancer, have low response rates and limited effects on improving patient survival. A recent Phase III clinical trial has demonstrated that nab-paclitaxel (Abraxane, a protein-bound paclitaxel) in combination with gemcitabine significantly improved response rate and overall survival compared to patients receiving gemcitabine alone. We previously demonstrated that targeting Notch signaling by anti-DLL4 (demcizumab) inhibits tumor growth, reduces tumor initiating cell frequency and induces differentiation in patient-derived pancreatic xenograft tumors. To further explore the utility of demcizumab in the setting of pancreatic cancer, we evaluated anti-DLL4 combination with gemcitabine/ nab-paclitaxel in a panel of pancreatic xenograft models. We found that anti-DLL4 in combination with gemcitabine plus nab-paclitaxel resulted in striking tumor regression, whereas tumors treated with chemotherapeutic agents alone grew continuously. The effect of the triple combination in some tumors was quite durable and persisted after both antibody and chemotherapeutic treatments were discontinued. The significant growth inhibitory effect by the combination of anti-DLL4 with gemcitabine/nab-paclitaxel was associated with a decrease in cancer stem cell frequency and an increase in apoptosis and tumor cell differentiation. The triple combination of anti-DLL4, gemcitabine and nab-paclitaxel was generally more efficacious compared with anti-DLL4 plus gemcitabine alone. Notably, in a xenograft established from a patient that previously did not respond to demcizumab plus gemcitabine, the triple combination was highly effective. We are currently evaluating demcizumab in combination with gemcitabine plus nab-paclitaxel in a Phase 1b clinical trial in pancreatic cancer. Citation Format: Wan-Ching Yen, Marcus Fischer, John Lewicki, Austin Gurney, Timothy Hoey. The combination of gemcitabine/nab-paclitaxel and anti-DLL4 (demcizumab) produces synergistic growth inhibition, delays tumor recurrence and reduces tumor initiating cells in pancreatic cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1898. doi:10.1158/1538-7445.AM2014-1898
Abstract 20466: De-Sumoylation and Phosphorylation of Magi1 Induce Microcirculation Dysfunction via Endothelial P90rsk Activation in Endotoxemia
Authors: Nhat Tu Le, Oksana Polesskaya, Carolyn J Giancursio, Minsoo Kim, Jack Taunton, Stephen Dewhurst, Anthony Pietropaoli, Keigi Fujiwara, Jun-Ichi Abe
Journal: Circulation (2014)

Background:  In sepsis, intermittent blood flow (a form of disturbed blood flow) occurs along with microcirculatory dysfunction, leading to multiple tissue/organ damage. Membrane associated guanylate kinase-1 (MAGI1) is a p90RSK-binding protein, but the functional significance of this association remains unknown.   Methods and Results:  When endothelial cells (ECs) were exposed to disturbed flow or thrombin, p90RSK was activated and MAGI1-S741 was phosphorylated. Normally, MAGI1 is SUMOylated at K931 and localized in the membrane/cytosol. However, after disturbed flow or thrombin stimulation, MAGI1 not only was phosphorylated at S741 but also was de-SUMOylated. These post-translational modifications occurred independently, and were significantly inhibited by dominant negative p90RSK adenovirus transduction (Ad-DN-p90RSK). Thrombin-induced NF-κB activation, E-selectin expression, and EC permeability measured by trans-endothelial electric resistance were significantly inhibited in ECs transduced by Ad-DN-p90RSK and Ad-MAGI1-S741A mutant. Expression of a p90RSK-MAGI1 binding inhibitory fragment (MAGI1aa362-543) significantly inhibited thrombin-induced NF-κB activation. In contrast to the MAGI1-S741A phosphorylation site mutant, MAGI1-K931R SUMOylation defect mutant enhanced thrombin-induced NF-κB activation and EC permeability, while MAGI1-SUMO3 chimera expression inhibited it. Together, these results suggest that MAGI1 de-SUMOylation plays a key role in up-regulating both EC inflammation and permeability. We then studied effects of FMK-MEA, a specific p90RSK inhibitor, on capillary perfusion in the cerebral cortex of mice exposed to endotoxin using in vivo 2-photon microscopy. p90RSK inhibition reduced the incidence of intermittent blood flow (disturbed flow) and the number of rolling leukocytes, and restored the velocity of capillary blood flow in endotoxemic mice. Systemic blood pressure, blood oxygenation, heart rate, and respiratory rate were not affected by FMK-MEA.   Conclusions:  MAGI1-S741 phosphorylation and MAGI1-K931 de-SUMOylation via p90RSK activation are critical in regulating endothelial inflammation and permeability and may play a major role in micro-circulatory dysfunction in sepsis.
Vascular Endothelial Genes That Are Responsive to Tumor Necrosis Factor- In Vitro Are Expressed in Atherosclerotic Lesions, Including Inhibitor of Apoptosis Protein-1, Stannin, and Two Novel Genes
Authors: Anton J.G. Horrevoets, Ruud D. Fontijn, Anton Jan van Zonneveld, Carlie J.M. de Vries, Jan Wouter ten Cate, Hans Pannekoek
Journal: Blood (1999)
Bird Flu in Cats
Authors: Joan Stephenson
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor
Authors: Daniel C. Lu, Shahrooz Rabizadeh, Sreeganga Chandra, Rana F. Shayya, Lisa M. Ellerby, Xin Ye, Guy S. Salvesen, Edward H. Koo, Dale E. Bredesen
Journal: Nature Medicine (2000)
Mitral Valve Repair for Functional Mitral Regurgitation in End-Stage Dilated Cardiomyopathy
Authors: Michele De Bonis, Elisabetta Lapenna, Giovanni La Canna, Eleonora Ficarra, Marco Pagliaro, Lucia Torracca, Francesco Maisano, Ottavio Alfieri
Journal: Circulation (2005)

Background— The aim of this study was to assess the results of mitral valve (MV) repair in functional mitral regurgitation because of end-stage dilated cardiomyopathy (DCM). Methods and Results— Seventy-seven patients with end-stage idiopathic (26 patients) or ischemic (51 patients) DCM underwent MV repair for functional mitral regurgitation (3 to 4+/4+). Fifty-eight patients (75.3%) were in New York Heart Association class III, and 19 (24.6%) were in IV. In 23 patients (29.8%) with a coaptation depth &lt;1 cm, an isolated undersized annuloplasty was used. In the remaining 54 (70.1%), with a coaptation depth ≥1 cm, the “edge-to-edge” technique was associated with the annuloplasty. In most of the cases (88.3%), a complete rigid/semirigid ring was used. Concomitant coronary artery bypass graft was performed in 39 patients (50.6%). Hospital mortality was 3.8% (3 of 77). Actuarial survival was 90.7±3.64%, and freedom from cardiac events was 81.8±7.96% at 2.7 years. At a mean follow-up of 18.4±9.8 months (range, 1 month to 5 years) New York Heart Association class improved from 3.4±0.4 to 1.4±0.6 ( P &lt;0.0001). Mitral repair failure (recurrence of MR ≥3+/4+) was documented in 7 patients (9%): 2 in the edge-to-edge (2 of 54, 3.7%) and 5 in the isolated annuloplasty group (5 of 23, 21.7%) ( P =0.03). Freedom from repair failure at 1.5 years was 95.0±3.4% and 77±12.1%, respectively ( P =0.04). The absence of the edge-to-edge was the only predictor of repair failure ( P =0.03). When residual MR was absent or mild, a reverse left ventricular remodeling was clearly documented. Conclusions— In patients with end-stage DCM, MV repair is feasible with low hospital mortality and important symptomatic improvement. The association of the edge-to-edge technique to the undersized annuloplasty can significantly improve the durability of the repair.
On the Day of Her Death
Authors: Ted McMahon
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fxr But Not Tgr5 Activation Stimulates Hco3-Rich Bile Secretion And Ameliorates Liver Damage In Mdr2-/- (Abcb4-/-) Mouse Model Of Chronic Liver Injury
Authors: Anna Baghdasaryan, Thierry Claudel, Judith Gumhold, Dagmar Silbert, Luciano Adorini, Frank Gonzalez, Kristina Schoonjans, Peter Fickert, Michael Trauner
Journal: Hepatology (2011)

Reference EPFL-CONF-170826View record in Web of Science Record created on 2011-12-16, modified on 2017-05-12
A memorable patient: The power of prayer
Authors: M D Manikal
Journal: BMJ (2000)

identification of these patients will enable the construction of practice or primary care group disease registers and help meet the objectives of the national service framework for coronary heart disease.Advice on the implementation of the method is available on the Battersea Research Group's website www.doh.gov.uk/brg/conduit3.htmlWe thank Professor Tony Kendrick for his encouragement at the start of this work, Andrew Tysoe Calnan for collecting the data, and the participating Battersea practices
Allogeneic blood stem cell transplantation: considerations for donors
Authors: Paolo Anderlini, Martin Körbling, David Dale, Alois Gratwohl, Norbert Schmitz, David Stroncek, Craig Howe, Susan Leitman, Mary Horowitz, Eliane Gluckman, Scott Rowley, Donna Przepiorka, Richard Champlin
Journal: Blood (1997)
Suppression of neutrophil superoxide generation by <scp>BNP</scp> is attenuated in acute heart failure: a case for ‘<scp>BNP</scp> resistance’
Authors: Saifei Liu, Doan T.M. Ngo, Cher‐Rin Chong, Anjalee T. Amarasekera, Nathan E.K. Procter, Giovanni Licari, Rustem F. Dautov, Simon Stewart, Yuliy Y. Chirkov, John D. Horowitz
Journal: European Journal of Heart Failure (2015)
Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NR-LU-10 whole antibody in LS174T colonic tumor-bearing mice.
Authors: Goldrosen Mh, Biddle Wc, Pancook J, Bakshi S, Vanderheyden Jl, Fritzberg Ar, Morgan Ac, Foon Ka
Journal: Cancer Research (1990)

Biodistribution, pharmacokinetic, and radioimaging studies were performed with 186Re-labeled NR-LU-10 whole antibody in athymic nude mice bearing the LS174T tumor growing either s.c. or in an experimental hepatic metastasis model. NR-LU-10 is an IgG2b murine monoclonal antibody (MAb) that reacts with virtually all human tumors of epithelial origin. NR-BC-1, a IgG2b murine MAb that reacts with normal human B-cell and B malignancies, was used as an isotype-matched control. These MAbs were radiolabeled with 186Re (3.7-day physical half-life; 1.07-MeV beta particle and 137-keV gamma, 9% abundance) by a preformed chelate approach by using the triamide thiolate ligand system. 186Re-labeled NR-LU-10 (50 microCi) was injected into nude mice bearing LS174T tumors growing s.c. Biodistribution studies revealed that the LS174T tumor retained the highest concentration of 186Re-labeled NR-LU-10 (5.3% injected dose/g) at day 6. The tumor:blood ratio ranged from 0.1:1 to 10.8:1 by day 6, the last day of analysis. In contrast the tumor:blood ratio of 186Re-labeled NR-BC-1, the isotype-matched MAb control, was 1:1 on day 6. Pharmacokinetic analysis indicated that the t1/2 beta of NR-LU-10 for blood and other tissues ranged from 21 to 25 h, while the t1/2 beta for the LS174T tumor averaged 52 h. The area under the curve for tumor compared to blood was 2.8- to 5.7-fold higher than the area under the curve for all other tissues and organs. The mean residence time for NR-LU-10 in blood and all other organs ranged from 23 to 26 h, while the mean residence time for NR-LU-10 in the LS174T tumor was 72 h. Scintigraphic images revealed selective uptake of the 186Re-labeled NR-LU-10, but not of the 186Re-labeled NR-BC-1, at the LS174T tumor site. Studies in an experimental model of hepatic metastasis revealed a similar selective pattern of 186Re-labeled NR-LU-10 accumulation. Scintigraphic images of the LS174T tumor growing within the athymic nude mouse liver were obtained. The biodistribution, pharmacokinetic, and scintigraphic image results suggest that 186Re-labeled NR-LU-10 shows promise as a therapeutic agent for gastrointestinal cancer.
Abstract 19195: A Central Role for CD68(+) Pulmonary Intravascular Macrophages in the Etiology of Hepatopulmonary Syndrome: Syndrome Reversal by Macrophage Depletion
Authors: Thenappan Thenappan, Ankush Goel, Glenn Marsboom, Yong-Hu Fang, Hannan J Zhang, Peter Toth, Hidemi Kajimoto, Jonathan Paul, Christian Wietholt, Zihgang Hong, Jalees Rehman, Stephen L Archer
Journal: Circulation (2010)
Abstract 16257: Is the Risk of Stroke and Death Really Different in Patients With Non Valvular Atrial Fibrillation and Flutter?
Authors: Sylvie Lang, Louise Boyer-Chatenet, Stephane Ederhy, Laure Soulat-Dufour, Clélie Van der Vynckt, Saroumadi Adavane, Nabila Haddour, Boccara Franck, Ariel Cohen
Journal: Circulation (2014)

Purpose:  Little and conflicting data exist regarding cardiovascular risks among non valvular atrial fibrillation (NVAF) and flutter (NVAFl) patients. This study aims to assess whether patient characteristics and risk factors, including CHA2DS2-VASc could identify patients with NVAF or NVAFl at higher risk for stroke and death.   Methods:  Between 1998 and 2011, 1,443 consecutive patients, hospitalised for NVAF or NVAFl were enrolled in the study. All patients were followed-up for at least six months. Cardiovascular events were recorded. The endpoint was defined as first occurrence of stroke or death. Kaplan-Meier (KM) survival curves estimates were compared using the Log Rank test. Association between arrhythmia type and outcome was evaluated using Cox models adjusted on all parameters defining the CHA2DS2-VASc score and treatments at discharge.   Results:  At admission, 151 patients presented NVAFl and 1,292 NVAF. The groups differed by age, sex, cardiovascular risk factors, and history of AF. The NVAFl patients were younger (26% vs. 37% were aged ≥75 years, p=0.003) and more frequently men (80% vs. 55%, p   Conclusion:  These results suggest that patients with non valvular atrial fibrillation or flutter have similar stroke and death risk at mid-term follow-up.